Upgrade

OS Therapies Incorporated

OSTX

Last
$1.62
Day
+0.0%
1y
-20.6%
5y
-35.5%
52w
-28.0%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1333d
EMA 21
1.64
EMA 50
1.66
EMA 200
1.67
20d high
-19.0%
5y high
-76.9%
5y range
9th
Website · 4 employees · United States

Positions held

Your positions

OSTX isn't in your positions.

Add it to see shares, cost, and P&L here.

Score
-31
Hold
avoid
Signal
Strong Sell
Target
$1.80
Stop
$1.47
Stop distance
9.3%
Target vs last
+11.1%

Fundamentals

Market cap$75.82MEnterprise value$75.59MTrailing P/E—Forward P/E4.67
PEG—Price / book-6.16Beta-0.64Dividend yield0.00%
Revenue growth—Earnings growth—Gross margin0.0%Operating margin0.0%
Profit margin0.0%ROE—ROA-2.3%Debt / equity—
Current ratio0.18Free cash flow-$1.69MAnalyst recommendationstrong_buyMean target$8.50
52w high$2.2552w low$1.15

Quarterly

2026-Q22026-Q12025-Q42025-Q32025-Q22025-Q1
Revenue$0.0M$0.0M$0.0M$0.0M$0.0M—
Op margin——————
Net income-$8.6M-$10.4M-$13.5M-$6.9M-$4.5M—
Gross margin——————
Gross profit——————
Operating income-$8.6M-$10.2M-$12.0M-$6.9M-$4.8M—

Yearly (6y)

20252024202320222021
Revenue$0.0M$0.0M$0.0M$0.0M—
Op margin—————
Net income-$28.8M-$8.9M-$7.8M-$6.3M—
Gross margin—————
Gross profit—————
Operating income-$28.7M-$6.8M-$4.3M-$4.4M—
Headline scan

No flags

• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).

News

2026-10-08 · Rubenstein Public Relations Named Agency of Record for OS Therapies

2026-10-07 · OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

2026-10-06 · OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

2026-10-01 · OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

2026-09-24 · OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

2026-09-21 · OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

2026-09-17 · OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

2026-09-15 · OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

2026-09-08 · OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial

2026-09-02 · OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance

2026-08-17 · OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates

2026-08-13 · OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

OSTX · daily-8.5% over 13 sessions
Close EMA21 EMA50 EMA200
1.451.551.651.761.862026-092026-092026-092026-092026-102026-102026-10
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin
-$13M-$10M-$7M-$3M$0M0%5%10%2025-Q22025-Q32025-Q42026-Q12026-Q2